Role of Tetrahydroxystilbene glucoside on bone formation in streptozotocin-induced diabetic rats

Kumarappan Chidambaram; Krishnaraju Venkatesan; Noohu Abdulla Khan; Premalatha Paulsamy; Kalpana Krishnaraju

Role of Tetrahydroxystilbene glucoside on bone formation in streptozotocin-induced diabetic rats

Authors
Kumarappan Chidambaram, Krishnaraju Venkatesan, Noohu Abdulla Khan, Premalatha Paulsamy, Kalpana Krishnaraju

Abstract
Polygonum multiflorum Thunb is a traditional medicinal herb that has long been used to treat age-related ailments. This herb contains tetrahydroxystilbene glucoside (TSG), also known as 2, 3, 5, 4-tetrahydroxystilbene-2-O—D-glucoside. The goal of this trial was to see if TSG could prevent bone loss in diabetic rats who were also given Canagliflozin. Polygonum multiflorum Thunb. is a traditional Chinese medicinal herb that has been widely used to treat age-associated diseases. Tetrahydroxystilbene glucoside (TSG), also known as 2, 3, 5, 4-tetrahydroxystilbene-2-O-β-D-glucoside, is a major component of this herb. The present study was designed to investigate the bone loss preventing activity of TSG in diabetic rats co-treated with Canagliflozin (CGF). The Wistar albino rats were placed into five groups, each with six rats: control (vehicle therapy), diabetic group, TSG group, Canagliflozin (CGF), and CGF + TSG group. For a period of 35 days, each medication was given through gastric gavage. TSG-treated diabetic rats had considerably higher levels of insulin and osteocalcin than diabetic control rats. TSG's effects in preventing or treating CGF induced bone loss in diabetic rats appear to be linked to a reduction in bone turnover. These data support the use of TSG as an osteoporosis treatment in diabetics.

Download | Pages : 31-33